"10.1371_journal.pone.0150241","plos one","2016-03-03T00:00:00Z","Liisa Sjöblom; Outi Saramäki; Matti Annala; Katri Leinonen; Janika Nättinen; Teemu Tolonen; Tiina Wahlfors; Matti Nykter; G Steven Bova; Johanna Schleutker; Teuvo L J Tammela; Hans Lilja; Tapio Visakorpi","Prostate Cancer Research Center, Institute of Biosciences and Medical Technology (BioMediTech), University of Tampere, Tampere, Finland; Fimlab Laboratories, Tampere University Hospital, Tampere, Finland; Department of Pathology, Fimlab Laboratories, Tampere University Hospital, Tampere, Finland; Prostate Cancer Research Center, School of Medicine, University of Tampere, Tampere, Finland; Department of Urology, Tampere University Hospital, Tampere, Finland; Departments of Laboratory Medicine, Surgery, and Medicine, Memorial Sloan Kettering Cancer Center, New York, United States of America; Nuffield Department of Surgical Sciences, University of Oxford, Oxford, United Kingdom; Department of Translational Medicine, Lund University, Malmö, Sweden","Conceived and designed the experiments: LS HL TV. Performed the experiments: LS OS MA KL TT. Analyzed the data: LS OS MA JN MN HL TV. Contributed reagents/materials/analysis tools: TW GSB JS TLJT TV. Wrote the paper: LS OS MA KL JN TT TW MN GSB JS TLJT HL TV.","Hans Lilja holds patents for free PSA (US 5,501,983), hK2 (U.S. Patent No. US 5,614,372), and intact PSA (U.S. Patent No. US 7,872,104 B2) assays, and is named on a patent application for a statistical method to detect prostate cancer. The assay patents and the patent application for the statistical model have been licensed and commercialized by OPKO and Dr. Lilja receives royalties from sales of these tests. Dr. Lilja owns stock in OPKO. Others do not disclose any COIs.","2016","03","Liisa Sjöblom","LS",13,TRUE,3,5,7,13,TRUE,TRUE,FALSE,0,NA,FALSE
